News stories about ProQR Therapeutics N.V. (NASDAQ:PRQR) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ProQR Therapeutics N.V. earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 47.7258529978174 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

These are some of the media headlines that may have impacted Accern Sentiment Analysis’s analysis:

Several analysts recently issued reports on PRQR shares. Zacks Investment Research raised shares of ProQR Therapeutics N.V. from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a report on Wednesday, August 30th. ValuEngine raised shares of ProQR Therapeutics N.V. from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective on shares of ProQR Therapeutics N.V. in a report on Tuesday, September 26th. Finally, JMP Securities increased their price target on shares of ProQR Therapeutics N.V. from $14.00 to $20.00 and gave the company an “outperform” rating in a report on Tuesday, September 26th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. ProQR Therapeutics N.V. has an average rating of “Buy” and an average target price of $18.88.

Shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) opened at $3.28 on Friday. The company has a quick ratio of 8.22, a current ratio of 6.72 and a debt-to-equity ratio of 0.20. ProQR Therapeutics N.V. has a 1-year low of $2.90 and a 1-year high of $6.90.

ProQR Therapeutics N.V. (NASDAQ:PRQR) last issued its quarterly earnings results on Monday, November 20th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.03. sell-side analysts forecast that ProQR Therapeutics N.V. will post -1.71 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “ProQR Therapeutics N.V. (PRQR) Receiving Somewhat Favorable News Coverage, Analysis Shows” was published by Watch List News and is the property of of Watch List News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at

About ProQR Therapeutics N.V.

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein.

Insider Buying and Selling by Quarter for ProQR Therapeutics N.V. (NASDAQ:PRQR)

Receive News & Ratings for ProQR Therapeutics N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.